Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults
Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults
复制标题
DOI：
10.1038/sj.ejcn.1602450
复制
发表时间：
2006-11-01
影响因子：
4.7
通讯作者：
Michaelsen, K. F.
中科院分区：
文献类型：
--
作者：
Larsen, C. N.;Nielsen, S.;Michaelsen, K. F.
目的：本研究旨在研究补充动物双歧杆菌乳酸亚种（BB-12）和副干酪乳杆菌副干酪亚种（CRL-431）对血脂、粪便恢复和排便习惯的剂量反应效应。粪便菌群的变化进行了分析，在10（10）CFU/天益生菌和安慰剂group.Design：该研究被设计为一个随机的，安慰剂对照，双盲，平行剂量反应study.Subjects：健康的年轻人（18 - 40岁）被招募的广告在当地报纸。在75名登记的人中，（46名女性，25名男性，平均年龄25.6岁（范围18 - 40岁））完成了研究。志愿者被随机分为五组，接受安慰剂或两种益生菌的混合物，浓度为10（8），10（9），在2周导入期、3周干预和2周洗脱期内，10（10）或10（11）CFU/天。在干预前、干预后即刻和干预后2周，记录患者的排便习惯和健康状况（腹胀、胀气和头痛），并检测血脂、BB-12和CRL-431的粪便回收率以及粪便微生物菌群。在接受10（11）CFU/天的组中，从15名志愿者中的13名回收了BB-12。在任何粪便样品中均未回收CRL-431。补充益生菌不会改变粪便细菌组成。观察到粪便稠度（稀便）随着益生菌剂量的增加而显著线性增加（P=0.018）。对血脂无总体剂量反应效应。结论：从粪便中观察到BB-12的剂量相关回收。赞助：本研究由Chr.汉森A/S，Hoersholm，丹麦赞助。
Objective: This study was performed to investigate the dose-response effects of supplementation with Bifidobacterium animalis subsp lactis (BB-12) and Lactobacillus paracasei subsp paracasei (CRL-431) on blood lipids, recovery from feces and bowel habits. Changes of the fecal microflora was analyzed in the 10(10) CFU/day probiotic and placebo group.Design: The study was designed as a randomized, placebo-controlled, double-blinded, parallel dose-response study.Subjects: Healthy young adults (18 - 40 years) were recruited by advertising in local newspapers. Of the 75 persons enrolled, 71 ( 46 women, 25 men, mean age 25.6 years ( range 18 - 40 years)) completed the study.Intervention: The volunteers were randomly assigned into five groups receiving either placebo or a mixture of the two probiotics in the concentration of 10(8), 10(9), 10(10) or 10(11) CFU/day in 2 weeks run-in period, 3 weeks intervention and 2 weeks wash-out. Diary reporting bowel habits and well being (abdominal bloating, flatulence and headache) was kept for all 7 weeks and blood lipids, fecal recovery of BB-12 and CRL-431, as well as fecal microflora was tested before, immediately and 2 weeks after intervention.Results: The fecal recovery of BB-12 increased significantly (P < 0.001) with increasing dose. In the group receiving 10(11) CFU/day BB-12 was recovered from 13 out of 15 volunteers. CRL-431 was not recovered in any of the fecal samples. Supplementation with probiotics did not change the fecal bacterial composition. A significant linear increase in fecal consistency (looser stool) with increasing probiotic dose (P=0.018) was observed. No overall dose - response effect was found on the blood lipids. High doses of probiotics were well tolerated.Conclusion: A dose-related recovery of BB-12 from feces was observed.Sponsorship: The study was sponsored by Chr. Hansen A/S, Hoersholm, Denmark.